Quick Hit: Lp(a) enters the standard lipid conversation

The 2026 ACC/AHA dyslipidemia guideline recommends measuring lipoprotein(a) at least once in adults as part of ASCVD risk assessment—an update that broadens the prevention conversation beyond LDL-C alone.

Prepared by: Iraq Cardiology Editorial Team
Source authors: Writing Committee Members, 2026 ACC/AHA Guideline on the Management of Dyslipidemia
Last reviewed: August 23, 2026
Reading time: 3 min

Quick summary

The essential point, in one sentence.

Reading companion

A professional question, bounded to this record.

Answers use this update and its recorded sources only; it does not provide individual treatment advice.

What changed

The 2026 ACC/AHA dyslipidemia guideline recommends measuring lipoprotein(a), or Lp(a), **at least once in all adults** for ASCVD risk assessment. The update also places Lp(a) alongside a broader risk discussion that can include apoB, triglycerides, clinical history, and selective imaging.

Why it matters

Lp(a) is a genetically influenced atherogenic lipoprotein. The practical editorial point is not that one biomarker answers every prevention question; it is that a complete lipid conversation may require more than a single LDL-C value.

Clinical boundary

This is a guideline update, not an individual testing or treatment instruction. Interpretation depends on the patient, the assay, the rest of the lipid profile, and the clinician's overall risk assessment.

Source

2026 ACC/AHA Guideline on the Management of Dyslipidemia.

Professional discussion starter

Turn reading into a balanced conversation.

Prompts for professional reflection—not individual treatment advice.

1Which element of the source most changes how your team would frame Preventive cardiology and dyslipidemia?
2Which limitation or context should be made explicit before discussing application?
3What question is worth taking to a journal club or multidisciplinary meeting?

Related updates

Clinical update

When a Coronary Stent Fails: Can Stentectomy Offer a Way Forward?

A new review suggests that catheter-based removal of a fully deployed coronary stent may be feasible in carefully selected cases of complex stent failure — but only within a highly specialized, imaging-led strategy.

Read update

Clinical update

Quick Hit: AF care quality moves from a checklist to a care pathway

The 2026 AHA/ACC atrial-fibrillation performance and quality measures put initial evaluation, stroke-risk documentation, prevention, equity, and shared decisions into one visible care-quality framework.

Read update